Reuters logo
BRIEF-‍Bavarian Nordic says BARDA exercised option under the contract for freeze-dried Imvamune
November 21, 2017 / 6:11 PM / in 21 days

BRIEF-‍Bavarian Nordic says BARDA exercised option under the contract for freeze-dried Imvamune

Nov 21 (Reuters) - Bavarian Nordic A/S:

* ‍BAVARIAN NORDIC ANNOUNCES EXERCISE OF CLINICAL OPTION BY US GOVERNMENT UNDER CONTRACT FOR FREEZE-DRIED IMVAMUNE SMALLPOX VACCINE​

* BAVARIAN NORDIC A/S SAYS ‍CONTRACT OPTION IS EXPECTED TO BE REVENUE RECOGNIZED BETWEEN 2018 AND 2022​

* BAVARIAN NORDIC- OPTION, WHICH REPRESENTS ABOUT $37 MILLION OF TOTAL CONTRACT OF UP TO $539 MILLION, WILL COVER DEVELOPMENT COSTS ASSOCIATED WITH PHASE 3 STUDY​

* ANNOUNCEMENT DOES NOT AFFECT COMPANY‘S EXPECTATIONS FOR FINANCIAL RESULTS FOR 2017​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below